Financing the next test of cell replacement

# Financing the next test of cell replacement OCTOBER 13, 2026 Aspen Neuroscience, a San Diego company that makes a Parkinson's cell therapy from a patient's own skin cells, has filed publicly for a Nasdaq IPO, according to Renaissance Capital. The therapy, sasineprocel, is investigational and not approved or available outside clinical trials. A patient-derived cell therapy carries a compelling biological idea into a demanding clinical and manufacturing process. An IPO would finance part of that journey, rather than resolve its uncertainties. The company filed on October 9, 2026, after a confidential submission on March 30, 2026. It plans to trade under the ticker ASPE. Renaissance Capital estimates the deal at up to $100 million. Leerink Partners, Piper Sandler and Stifel are the bookrunners. Aspen's lead product is sasineprocel. According to the source, it is a single-dose therapy designed to replace the dopamine-producing neurons lost in Parkinson's disease. It is made from the patient's own cells. The product holds two FDA designations, RMAT and Fast Track, according to the source. As of August 18, 2026, 15 patients had been dosed in an open-label Phase 1/2a trial. Open-label means patients and doctors know what is being given. The company says that, after FDA feedback, it expects to dose its first Phase 3 patients in the second half of 2027. Renaissance Capital lists Aspen as founded in 2018, with about 120 employees. For investors, the offering is a direct test of appetite for a regenerative approach in an age-related neurodegenerative disease. The company is selling shares with only 15 patients dosed and a pivotal trial still ahead. The size of the raise, the pricing and the demand will show how much weight the market gives to early data and regulatory designations at this stage. Those outcomes are not yet known. Readers with Parkinson's should not start or stop any medication or treatment without consulting their clinician. WHAT TO WATCH NEXT Whether Aspen sets a price range and completes the listing, and what FDA feedback means for its Phase 3 timing. The next trial will matter more than the appeal of the concept. It is the place where the possibility of replacing lost function must become measurable. Source: Renaissance Capital ---